Crimean–Congo hemorrhagic fever (CCHF) is a high‑risk viral disease transmitted by ticks and livestock that can cause rapid fever, organ failure and internal bleeding, and it has no approved vaccines or treatments. A new preclinical study in npj Vaccines reports encouraging results for an experimental vaccine tested in mice. The work comes from a team that includes Scott Pegan at the University of California, Riverside and collaborators at several public agencies.
The vaccine platform is a virus-like replicon particle: it enters cells like the real virus but lacks the genetic material needed to replicate, so it cannot cause infection. Unlike most vaccines that target surface proteins, this candidate focuses on internal proteins, particularly the N protein that is normally hidden inside the virus. The authors suggest the N protein focus may underlie the unusually rapid antibody response and the platform's success.
Earlier work showed protection within three days of a single dose. In the new study researchers measured antibodies after one or two doses and found them detectable for up to 18 months in mice, an interval the team says roughly corresponds to several years in humans. Antibody levels in one- and two-dose groups were similar for about nine months, while animals receiving a booster developed stronger, more stable antibodies and showed better, longer-lasting protection.
Next steps include scaling production under Good Manufacturing Practice (GMP) ahead of human clinical trials. Partners at the Centers for Disease Control and Prevention are already exploring the same platform for other pathogens such as Nipah virus. The study lists collaborators at the CDC, the US Department of Agriculture and Auburn University, and notes partial support from the CDC and the National Institute of Allergy and Infectious Diseases of the NIH; the findings do not necessarily represent the official CDC position.
Difficult words
- replicon particle — a noninfectious agent that mimics virus entry into cells
- n protein — an internal viral protein normally hidden inside the virus
- good manufacturing practice (GMP) — rules and processes ensuring safe, quality production
- preclinical — research done before human clinical trials
- booster — an extra vaccine dose to increase immunity
- antibody — a blood protein that fights infectionantibodies
- transmit — to pass a disease from one to anothertransmitted
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What advantages or disadvantages might come from targeting an internal viral protein like the N protein rather than a surface protein?
- The study found similar antibody levels after one and two doses for about nine months. How could this result affect decisions about vaccination schedules?
- Partners are testing this platform for other pathogens. Why might researchers try the same vaccine platform for different viruses, and what factors would influence that decision?
Related articles
Ancestral healing in the Caribbean
Ancestral healing asks societies to face historical wounds so people can live healthier lives. In the Caribbean, educators combine shamanic practices, nervous-system work and cultural rituals with scientific findings about trauma and community care.
PAHO issues first guide for tungiasis treatment
PAHO has published the first evidence-based guide to treat tungiasis, recommending low-viscosity dimethicone and warning against unsafe manual removal. The disease affects millions in Latin America, the Caribbean and Sub-Saharan Africa.